AMARIN CORPORATION PLC

Consensus Amarin Corporation plc Deutsche Boerse AG

Stocks

EH3

US0231114044

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG Other stock markets 15:45:29 2026-07-31 EDT			5-day change	1st Jan Change
12.30 ^EUR	+1.65%		+4.24%	+3.36%

07-29	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-29	European Equities Traded in US as ADRs Ease in Wednesday Trading	MT

Evolution of the Average Target: Amarin Corporation plc

Evolution of the Target Price: Amarin Corporation plc

Changes in Analyst Recommendations: Amarin Corporation plc

1997960179109e7a6.kAw87-xph_0Jlju-VAFbyUErf1PgHCSS4mf4FlCNBFg.431E3Zs9xMVFu2iLMHYIqzJfBRK4XWPHkCyQYgG0WyqpZgWBvArotW7ubg~2542d1eabf10866eb1432dd08abab44a

Analysts' recommendations: Amarin Corporation plc

25-10-27	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25-06-25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
23-10-25	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
23-07-19	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
23-01-06	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT
22-10-19	SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating	MT
22-05-06	JPMorgan Downgrades Amarin to Underweight From Neutral	MT
22-05-05	HC Wainwright Lowers Amarin to Neutral From Buy, Price Target to $3 From $10	MT
22-05-05	SVB Leerink Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $3 From $10	MT
22-05-05	Northland Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $2 From $9	MT
22-02-16	SVB Leerink Adjusts Amarin's Price Target to $10 from $11, Maintains Outperform Rating	MT
22-01-31	SVB Leerink Adjusts Amarin's Price Target to $11 from $12, Keeps Outperform Rating	MT
21-05-12	AMARIN : Goldman Sachs Downgrades Amarin to Sell From Neutral, Adjusts Price Target to $5 From $6	MT
21-02-01	AMARIN : SVB Leerink Adjusts Price Target on Amarin to $16 From $12, Maintains Outperform Rating	MT
20-12-23	AMARIN : Goldman Sachs Adjusts Amarin's Price Target to $6 From $8, Maintains Neutral Rating	MT
20-12-07	AMARIN : Citigroup Adjusts Amarin's Price Target to $7 from $12, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+17.16%
	ARGENX SE					+20.44%
	BIONTECH SE					+34.66%
	INSMED INCORPORATED					+98.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.54%
	GENMAB A/S					+28.71%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+17.22%
	EXELIXIS, INC.					-1.82%
	PHARMAESSENTIA CORPORATION					+1.26%
	Average					+26.46%
	Weighted average by Cap.					+26.35%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

SELL

Number of Analysts

1

Last Close Price

14.26USD

Average target price

12.00USD

Spread / Average Target

-15.85%

High Price Target

12.00USD

Spread / Highest target

-15.85%

Low Price Target

12.00USD

Spread / Lowest Target

-15.85%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Jefferies & Co.
Northland Securities
SVB Securities LLC
JPMorgan Chase
SVB Leerink
HC Wainwright
Goldman Sachs

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

SELL

Number of Analysts

1

Last Close Price

14.26USD

Average target price

12.00USD

Spread / Average Target

-15.85%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
AMRN Stock
EH3 Stock
Consensus Amarin Corporation plc

The best tools reserved for subscribers to boost the performance of your investments!